NEW YORK (GenomeWeb News) – Quintiles today announced it will contribute $2.6 million over four years to a public-private initiative to develop better breast cancer therapies using genetic and other biomarkers.
The funding will support I-SPY 2, a five-year, $27 million cancer trail started last year to screen new breast cancer drugs. Quintiles will make its contribution to the trial through QuantumLeap Healthcare Collaborative, a non-profit foundation and a co-project manager of I-SPY 2.
"Quintiles' $2.6 million grant and our joining the I-SPY 2 management consortium reflect the company's unwavering commitment to patients," Dennis Gillings, chairman and CEO of Quintiles, said in a statement. "Multi-party collaboration, adaptive trial design, biomarker use, and point-of-care data access are major steps in the right direction."
I-SPY 2 — which stands for Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis — is managed by the Biomarkers Consortium, a collaboration between the Foundation for the National Institutes of Health, the NIH, the US Food and Drug Administration, and biopharmaceutical firms.
The I-SPY 2 trial involves 800 patients with advanced breast cancer at the time of primary diagnosis. In innovative adaptive trial designs, biomarkers from individual patient tumors are used to screen multiple investigational therapies simultaneously so that researchers can evaluate each therapy's effectiveness.
The goal is to develop breast cancer therapies at half the amount of time and one-fifth the cost it takes to develop such therapies. Currently, development efforts take between 12 and 15 years and more than $1 billion.
Financial supporters of I-SPY 2 include the Safeway Foundation, QuantumLeap Healthcare Collaborative, several biopharma firms, and private donors.
Based in Research Triangle Park, NC, Quintiles is a fully integrated bio and pharmaceutical services provider and offers clinical, commercial, consulting, and capital solutions.